Less than a tenth of patients who could benefit from obesity jabs like Wegovy can access them, states the World Health Organization as it publishes its inaugural recommendations on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for increased and just access to these injectable treatments.
According to forecasts, more than two billion are projected to be living with obesity by 2030 without intervention.
"The latest guidance acknowledges that obesity is a long-term condition that can be addressed with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major obstacles to broad access to the injections that can aid individuals in losing substantial weight, explains the agency.
Skinny Jab Scarcity
Even in the present best projected case, the supply of such drugs could only cover about 100 million people – fewer than 10% of eligible patients, per the health organization.
The guideline encourages nations and manufacturers to increase availability, by approaches such as voluntary licensing.
The intellectual property rights on the active ingredient – the main ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.
How Obesity Drugs Function
GLP-1 drugs imitate a body's own hormone to slow digestion, reduce hunger and enhance the sense of being full so users eat less.
Individuals usually begin shedding pounds within a few weeks of starting on the once-weekly jabs.
Research suggests patients may put most of the weight back on within a year of halting the treatment, as their usual appetite resume.
Being overweight or obese elevates your chance for experiencing health problems, like diabetes, heart disease, brain attack, and some cancers.
Excess weight impacts individuals in every country and was associated with millions of deaths worldwide in 2024, per the WHO.
